Teng Li1, Jing Yu1, Xinyu Luo1, Weiguo Ren2, Yue Zhang1, Bangwei Cao3. 1. Cancer center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China. 2. Department of Endocrinology and Oncology, Beijing Nanyuan Hospital, Beijing 100076, China. 3. Cancer center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China. Electronic address: oncology@ccmu.edu.cn.
Abstract
BACKGROUND: Expression of VEGFRs may affect cancer prognosis. The aim of this work is to evaluate the prognostic significance of VEGFRs of patients with gastric cancer. METHODS: The databases PubMed, Embase, Web of Science, and Cochrane Library as well as ASCO and ESMO were searched systematically for articles reporting the prognostic significance of tissue VEGFRs in gastric cancer. The statistical analyses were carried out using Stata version 12.0. RESULTS: A total of 8 articles comprising 950 patients were eligible for meta-analysis. The combined HR of studies evaluating total VEGFRs overexpression was 1.42 (95% CI 1.01-2.00, P = 0.044), suggesting that it had prognosis significance in overall survival of gastric cancer. Subgroup analysis showed that it was VEGFR-2 (HR 1.81, 95% CI 1.31-2.49, P < 0.001) but not VEGFR-3 (HR 0.91, 95% CI 0.45-1.82, P = 0.787) overexpression was associated with an increased risk of median overall survival (mOS) and it can be a potentially predictive biomarker for gastric cancer. CONCLUSIONS: VEGFR-2 overexpression is a promising negative prognosis predictor for patients with gastric cancer. The prognosis significance of VEGFR-3 still need further study.
BACKGROUND: Expression of VEGFRs may affect cancer prognosis. The aim of this work is to evaluate the prognostic significance of VEGFRs of patients with gastric cancer. METHODS: The databases PubMed, Embase, Web of Science, and Cochrane Library as well as ASCO and ESMO were searched systematically for articles reporting the prognostic significance of tissue VEGFRs in gastric cancer. The statistical analyses were carried out using Stata version 12.0. RESULTS: A total of 8 articles comprising 950 patients were eligible for meta-analysis. The combined HR of studies evaluating total VEGFRs overexpression was 1.42 (95% CI 1.01-2.00, P = 0.044), suggesting that it had prognosis significance in overall survival of gastric cancer. Subgroup analysis showed that it was VEGFR-2 (HR 1.81, 95% CI 1.31-2.49, P < 0.001) but not VEGFR-3 (HR 0.91, 95% CI 0.45-1.82, P = 0.787) overexpression was associated with an increased risk of median overall survival (mOS) and it can be a potentially predictive biomarker for gastric cancer. CONCLUSIONS:VEGFR-2 overexpression is a promising negative prognosis predictor for patients with gastric cancer. The prognosis significance of VEGFR-3 still need further study.
Authors: Gong Hongxia; Jin Xiaojie; Leng Guangxian; Zhang Min; Niu Shiwei; Cao Wangjie; Zhang Han; Zeng Yuanding; Li Chenghao; Li Yaling; Su Yun; Liu Yongqi Journal: J Oncol Date: 2022-04-25 Impact factor: 4.501